Apple (NASDAQ:AAPL) closed within roughly 4% of overtaking Nvidia (NASDAQ:NVDA) as the most valuable company in the United States, driven by fresh product pipeline optimization.
Nvidia (NASDAQ:NVDA) saw its equity valuation pull back to levels relative to its forward earnings capacity not seen since early 2019, before the generative artificial intelligence buildout reset broader capital market indices.
Chevron Technical Center, a division of Chevron U.S.A. (NYSE:CVX) and a subsidiary of Chevron Corporation, has finalized a technology licensing agreement allowing ZL Chemicals to commercialize its proprietary advanced chemical surfactant technology.
Ed Yardeni, president of Yardeni Research, says the flare-up of fighting with Iran rekindles market concern that rising oil prices will stoke inflation -- and force the Federal Reserve to hike interest rates. He speaks on Bloomberg Television's ``Surveillance.''
Baker Hughes (NASDAQ:BKR) and Kodiak Gas Services (NYSE:KGS) have finalized a multi-year strategic agreement to design and deploy custom gas turbine power solutions aimed at addressing rapid power constraints in U.S. data center and energy infrastructure markets.
Seres Therapeutics (NASDAQ:MCRB) reported positive early clinical data from a 15-patient investigator-sponsored study evaluating its microbiome candidate SER-155 in patients with immune checkpoint inhibitor-related enterocolitis.
Wrap Technologies, Inc. (NASDAQ:WRAP) announced a strategic transaction securing exclusive United States and NATO commercialization rights to Frenel Imaging’s physics-based artificial intelligence sensing technology.
Palladyne AI (NASDAQ:PDYN) reported preliminary financial results for the second quarter of fiscal 2026, with revenue increasing to approximately $5.8 million from $1 million in the same quarter of 2025.
OKYO Pharma (NASDAQ:OKYO) received positive regulatory feedback from the United States Food and Drug Administration following a Type D consultation to advance its ophthalmic candidate urcosimod into a global Phase 3 pivotal trial.
Prime Medicine (NASDAQ:PRME) secured a definitive binding arbitration victory against Beam Therapeutics regarding the clinical development rights for its Alpha-1 Antitrypsin Deficiency pipeline asset PM647.
UroGen Pharma (NASDAQ:URGN) received United States FDA clearance for its Investigational New Drug application to initiate clinical evaluations of its next-generation oncolytic virus treatment UGN-501.
Azenta (NASDAQ:AZTA) completed the sale of its B Medical Systems business to Thelema S.à r.l. on July 1, 2026.
_1435550_640x360_2505931331884-640x360.webp&w=3840&q=75)
